![Alborz Yazdi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alborz Yazdi
Gründer bei Exavir Therapeutics
Profil
Alborz Yazdi is the founder of Exavir Therapeutics.
Prior to that, he worked as an Analyst at Passaic Capital Management LLC from 2020 to 2022 and as an Associate at Bain Capital Life Sciences LP from 2019 to 2020.
He completed his undergraduate degree at Yale University.
Aktive Positionen von Alborz Yazdi
Unternehmen | Position | Beginn |
---|---|---|
Exavir Therapeutics
![]() Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Gründer | - |
Ehemalige bekannte Positionen von Alborz Yazdi
Unternehmen | Position | Ende |
---|---|---|
Passaic Capital Management LLC
![]() Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Analyst-Equity | 01.02.2022 |
Bain Capital Life Sciences LP
![]() Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Private-Equity-Analyst | 01.10.2020 |
Ausbildung von Alborz Yazdi
Yale University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Passaic Capital Management LLC
![]() Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Finance |
Bain Capital Life Sciences LP
![]() Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Finance |
Exavir Therapeutics
![]() Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Commercial Services |